During the recent 30 years, there has been a dramatic increase in knowledge about the role
of aldosterone and the mineralocorticoid receptor (MR) in the pathophysiology of …

Risk factors such as hypertension and diabetes are known to augment the activity and tissue
expression of angiotensin II (Ang II), the major effector peptide of the renin–angiotensin …

Thrombosis has threatened human health in past decades. Bacillus nattokinase is a
potential low-cost thrombolytic drug without side-effects and has been introduced into the …

Introduction: The age-standardized death rate from diabetic kidney disease increased by
106% from 1990 to 2013, indicating that novel therapeutic approaches are needed, in …

Objective The objective of this study is to evaluate the effects of consumption of nattokinase
on hypertension in a North American hypertensive population with associated genetic …

Abstract In April 2019, two major Phase 3 randomized clinical trials were published that
assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes …

The renin–angiotensin–aldosterone system (RAAS) ranks among the most challenging
puzzles in cardiovascular medicine. It participates in the principal homeostatic mechanisms …

Background: Naringenin, a member of the dihydroflavone family, has been shown to have a
protective function in multiple diseases. We previously demonstrated that naringenin played …

Diabetic kidney disease is one of the most frequent complications in patients with diabetes
and constitutes a major cause of end-stage kidney disease. The prevalence of diabetic …

Introduction: Renin–angiotensin system (RAS) blockers are in clinical use to treat high blood
pressure and proteinuric chronic kidney disease. However, RAS blockade is limited by the …